Washington University/Siteman Cancer Center leading a national cancer trial network
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITE
This program helps Washington University/Siteman Cancer Center run and enroll patients in national cancer treatment and control trials, including molecularly targeted and rare cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11289863 on NIH RePORTER |
What this research studies
As a patient, this program means Washington University/Siteman Cancer Center will lead and support national cancer clinical trials, offering more trial options locally. The center provides scientific leadership, mentors clinicians, and helps design therapeutic, correlative, and cancer-control trials across many cancer types. WU/Siteman partners with national groups (Alliance, ECOG-ACRIN, NRG) and aims to maintain strong enrollment, especially for molecularly driven and rare cancers. The leadership team includes experienced cancer specialists across medical oncology, gynecologic oncology, radiation oncology, and radiology, and the site has enrolled over 1,200 patients since 2019.
Who could benefit from this research
Good fit: Ideal candidates are people with cancer receiving care at Washington University/Siteman or affiliated clinics who are willing and eligible to join national therapeutic, correlative, or cancer-control trials.
Not a fit: People without cancer, those not treated at or unable to travel to WU/Siteman or its affiliates, or patients who do not meet specific trial eligibility criteria may not benefit directly from this program.
Why it matters
Potential benefit: If successful, patients could gain faster access to a wider range of national cancer trials and more options for molecularly targeted or rare tumor treatments.
How similar studies have performed: Cooperative group and NCTN lead sites have a strong track record of expanding trial access and accrual, and WU/Siteman has enrolled over 1,200 patients since 2019.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Bartlett, Nancy L — Washington University
- Study coordinator: Bartlett, Nancy L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.